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ABSTRACT  
Objective: To identify factors associated with mother-to-child HIV-1 transmission (MTCT) 
from mothers receiving antenatal antiretroviral therapy. 
Design: The French Perinatal Cohort (EPF), a multicenter prospective cohort of HIV infected 
pregnant women and their children. 
Methods: Univariate analysis and logistic regression, with child HIV status as dependant 
variable, were conducted among 5271 mothers who received antiretroviral therapy during 
pregnancy, delivered between 1997 and 2004 and did not breastfeed. 
Results: The MTCT rate was 1.3% (67/5271 ; 95% confidence interval [CI], 1.0 -1.6). It was as 
low as 0.4% (5/1338 ; 95% CI, 0.1 - 0.9) in term births with maternal HIV-1 RNA level at 
delivery below 50 copies/mL. MTCT increased with viral load, short duration of antiretroviral 
therapy, female gender and severe premature delivery: 6.6% before 33 weeks versus 1.2% at 37 
weeks or more (p<0.001). The type of antiretroviral therapy was not associated with 
transmission. Intrapartum therapy was associated with 4-fold lower MTCT (p=0.04) in case of 
virological failure (> 10 000 copies/mL). Elective cesarean section tended to be inversely 
associated with MTCT in the overall population, but not in mothers who term delivered with 
viral load < 400 copies/mL (OR: 0.83;  0.29-2.39; p=0.37). Among them, only duration of 
antenatal therapy was associated with transmission (OR by week: 0.94; 0.90-0.99; p=0.03).  
Conclusions:  Low maternal plasma viral load is the key factor for preventing mother-to-child 
transmission. Benefits in term of MTCT may be expected from early antiretroviral prophylaxis. 
Potential toxicity of prolonged antiretroviral use in pregnancy should be evaluated.  
 
Key words: HIV, prevention of mother-to-child transmission, epidemiology, cohort, 
public health 
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Over the decade following the landmark PACTG076/ANRS024 American-French trial in 1994, 
a spectacular decrease in mother-to-child transmission of HIV-1 (MTCT) has been obtained in 
industrialized countries [1]. Transmission rates on the order of 1 – 2% have been reported for 
several years [2-5]. While  these results were first obtained using zidovudine with elective 
cesarean section, or a combination of zidovudine and lamivudine, the more recent consensus [6, 
7] is to use highly active antiretroviral therapy (HAART) for the prevention of transmission, 
even in women without an indication for themselves.  A number of specific considerations 
concerning the use of such aggressive regimens during pregnancy still need to be addressed, 
including optimal use of HAART in reducing the risk for perinatal transmission, effects on 
pregnancy outcome,[8-14] and whether elective cesarean is required in women receiving active 
therapy who have an undetectable plasma viral load at delivery [4, 12, 15-18]  
Our objective was to estimate the MTCT rate and to evaluate the role of the various components 
of prophylaxis in the HAART era.  At the opposite of most of the studies which included 
mothers who failed to receive any prophylaxis, the large number of mother-child pairs included 
in the French Perinatal Cohort provided the opportunity to focus on exclusively women who 
received antiretroviral therapy (ART) during pregnancy, especially with no obvious potential 
risk factors such as prematurity or virological failure at delivery.  
 
Subjects and Methods 
The French Perinatal Cohort (EPF) 
Since 1986, the EPF has prospectively enrolled HIV-infected women who delivered in 90 
centers throughout France, except in case of parental refusal. Children were followed up 
according to recommended standards of care [7], including clinical and biologic examination at 
birth, 1, 3, 6, 12 and 18-24 months, and then every 6 months  for infected children, as previously 
reported [19]. No specific recommendation for HIV treatment and obstetrical care was made for 
women included in the cohort, although French national guidelines for prevention of MTCT 
were regularly published and updated[7]. The national policy since 1993 is to offer universal 
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voluntary HIV testing as a part of prenatal care. Antenatal prophylaxis was initially based on 
zidovudine monotherapy or on dual nucleosidic therapy since 1997, with elective cesarean 
section according to risk/benefit evaluation. HAART was recommended to mothers with viral 
load above 10 000 copies/mL in 2002 and to all mothers in 2004. Since 2002, elective cesarean 
section was not recommended for those who delivered under HAART with viral load below 400 
copies/mL. In all cases, intrapartum zidovudine infusion and neonatal prophylaxis were 
recommended. This cohort study was approved, according to French laws, by the Hôpital 
Cochin IRB and the French computer database watchdog commission (Commission Nationale 
de l’Informatique et des Libertés).  
 
Study population 
All HIV-1 infected women who delivered in mainland France EPF sites between January 1, 
1997 and December 31, 2004 were included if they met the following criteria: (1) they received 
at least one antenatal ART at any time during pregnancy (except exclusive intrapartum 
prophylaxis); (2) they did not breastfeed (99.8% of treated mothers); (3) the child’s infection 
status was documented. Breastfeeding status was recorded during the postnatal hospitalization, 
and at each protocol visit. An infant was considered as infected if HIV-1 was detected by 
virologic tests on two separate samples (HIV1-PCR DNA or HIV RNA or PBMC viral culture 
or p24 antigenemia) or if anti-HIV1 antibodies detected by ELISA and Western Blot persisted 
after 18 months of age. An infant was considered as non infected if virologic tests were negative 
on two separate samples, of which at least one taken after termination of the neonatal 
prophylactic treatment or if serological testing was negative after 18 months. Laboratory tests 
were done on sites. HIV-1 RNA quantification in plasma were assessed by either the Roche 
Amplicor Monitor Test version 1.5 (Roche Diagnostic Systems, Basel, Switzerland) or branched 
DNA (Quantiplex, Versant, Bayer HealthCare, Tarrytown, USA); HIV-1 PCR DNA in PBMC 
were performed using the Roche Amplicor Monitor Test with modifications as described [20], 
or using the real time PCR following the ANRS method [21].  Lastly, for few specific cases, 
PBMC viral culture was performed as described[22].  
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Among the 6587 HIV-1 infected women who delivered in the study period, 219 declined 
enrollment or terminated pregnancy, 118 were infected by HIV-2 exclusively, 226 did not 
receive antenatal ART (including 124 who received intrapartum ART prophylaxis), 12 
breastfed. For 472 mothers, ART or breastfeeding status were missing, mostly due to delay in 
the return of questionnaires not related to maternal or children characteristics. Among the 5540 
mothers who received ART and did not breastfeed, the child’s HIV status could not be 
established for 42 stillbirths, 14 neonatal deaths, and for 213 (3.8%) children because of 
incomplete virological data. For 117 multiple pregnancies, only the first born was included for 
estimation of the transmission rate. Overall, 5271 mother-child pairs, from 77 sites, were 
enrolled in analysis performed on data updated in January, 2007.  
 
Variables 
We recorded demographics including geographical origin, gestational age at booking visit in the 
obstetrical center, levels of plasma HIV1 RNA and CD4 cell count nearest to the time of 
delivery no more than 7 days after delivery, type and number of antiretroviral combinations 
received during pregnancy, mode of delivery (vaginal, emergency cesarean section or elective 
cesarean section, defined as before labor and before rupture of the membranes), and gestational 
age at delivery. Adherence was not recorded.  
The last combination of ART prescribed before delivery was considered for analysis. It was 
categorized into three classes: monotherapy of nucleoside reverse transcriptase inhibitor 
(NRTI), almost exclusively with zidovudine, dual-drug therapy (two NRTI, mostly zidovudine-
lamivudine), or HAART (three or more drugs of any class). The antenatal ART duration was 
calculated as the number of weeks between the first initiation of antenatal ART and delivery. 
When a treatment interruption of at least 15 days was prescribed for women who were receiving 
ART at the onset of pregnancy, the antenatal ART duration was calculating beginning at 
reintroduction of ART.  
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Maternal intrapartum prophylaxis was classified as none versus intravenous zidovudine and/or 
single-dose nevirapine. Neonatal prophylaxis initiated within 3 days, was classified as: none or 
zidovudine monotherapy or 2 or more antiretroviral drugs. 
 
Statistical analysis 
We first studied whether viral load and prematurity were related to transmission, independently 
of one another and of other factors likely to play a part in the maternal transmission of HIV. 
Percentages were estimated with their exact 95% confidence intervals and compared by using 
Chi-square or 2-tailed Fisher exact test and continuous variables by Student or Wilcoxon rank 
test. Interaction between prematurity and viral load was investigated in stratified analysis. We 
assessed, for all births, term births and term births with viral load <400 copies/mL, the validity 
of linear assumption between transmission rate and duration of ART by fitting a generalized 
additive model (GAM)  with S+ software [23], estimated by smoothing cubic splines [24]. 
A backward stepwise logistic regression was performed with the child’s HIV status as the 
dependant variable. The significance p-value level for removal was fixed to 0.25, using the 
likelihood-ratio test. The initial model included four groups of non collinear variables. The first 
group represented each component of prophylaxis strategy: duration of antenatal ART, type of 
last ART, mode of delivery, intrapartum prophylaxis, and type of neonatal prophylaxis. Type of 
first antenatal ART and time of initiation, number of changes during pregnancy, or duration of 
last antenatal ART were analyzed but not included in the final model because of colinearity. The 
second group of variables included the last viral load and CD4 cell count, which depended not 
only on the antenatal prophylaxis but on their level at starting pregnancy, unrecorded for most 
of these women. The third group included prematurity and gender of neonate. The fourth group 
comprised available characteristics potentially related to access or adherence to care 
management: year of delivery, parity, maternal age, geographical origin, active drug use and 
gestational age at booking.  
We then excluded premature births (<37 weeks) to perform stepwise logistic regressions in two 
subgroups, according to virological failure (viral load > 10 000 copies/mL) or success at 
H
AL author m
anuscript    inserm
-00204104, version 1
  
delivery (<   400 copies/mL ), which represented respectively 7% and  54% of the whole study 
population. 
Analyses were conducted using the STATA software [25] . P<0.05 was used to determine 
statistical significance. 
 
Results 
 
Characteristics of the population 
Overall, 5271 eligible mother-child pairs with deliveries between 1997 and 2004 were enrolled. 
At end-point, the median follow up for included children was 19 months (interquartile range:15-
24). The use of HAART increased from 3% in 1997 to 53% in 2001 and 79% in 2004, while 
low maternal viral load at delivery (< 400 copies/ml) increased from 47% to 79%. During that 
period, CD4 cell count remained stable (10% below 200 cells/mm3 and 68% for 350 or over). In 
2004, 54% of mothers who were receiving HAART as last antenatal ART delivered with 
undetectable HIV-RNA level (<50 c/mL). Overall, 19% of treated women were receiving 
monotherapy, 33% dual-drug therapy, and 48% HAART at delivery (Table 1). The HAART 
combination included two NRTI and a Protease inhibitor (PI) in 73% of cases, two NRTI and a 
Non Nucleoside Reverse Transcriptase Inhibitor (NNRTI) in 17%, NRTI, PI and NNRTI in 3% 
and three or more NRTI exclusively in 7%. The proportion of elective cesarean increased from 
14% in 1997 to 56% in 2000 and tended to decrease to 41% in 2004, whereas if was stable for 
emergency cesarean section (29%). Ninety six percent received intrapartum prophylaxis, which 
was intravenous zidovudine alone or associated with single dose of nevirapine in 6% of cases. 
All neonates, except 0.7 %, started within the 3 days after birth a 4 to 6 weeks course of 
postnatal prophylaxis, mainly zidovudine monotherapy (76%). Characteristics according viral 
load at delivery are presented in table 1. 
 
Risk factors according to gestational age at delivery 
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Among the 5271 neonates, 67 were infected, an overall MTCT rate of 1.3% (95% CI: 1.0 -1.6). 
The univariate analysis (Table 2) showed a significant association with prematurity (p<0.001), 
HIV1 RNA level (p<0.001), CD4 cell count (p<0.001), and duration of ART during the 
pregnancy (p<0.001).  The transmission rate was 6 times higher for neonates born before 33 
weeks (6.6%; 95%CI: 2.9-12.5) than for full-term infants (1.1%; 95%CI: 0.8-1.5), but was not 
increased for those born between 33 and 36 weeks (1.2%; 95%CI: 0.5-2.5). The rate increased 
with delivery viral load in term (p<0.001) as well in premature births (p<0.001), with no 
significant interaction between viral load and prematurity (p=0.18; fig 1):  overall, the rate was 
0.6% (95%CI: 0.4-0.9) below 400 c/mL, reached 1.5% (95%CI: 0.8-2.5) between 1,000 and 
10,000 c/mL, and 6.8% (95%CI: 4.6-9.6) over 10,000 c/mL; however, among severe premature 
births, the rate passed from 1.7% below 400 c/mL to more than 11% for each categories over 
400 c/mL (fig 1). The median duration of ART during pregnancy was significantly shorter in 
mothers of infected than non infected children (9.5 versus 16 weeks globally, p<0.001 ; 11 
versus 16 weeks in term births, p=0.001; 5 versus 17 weeks in premature births, p=0.002). The 
relationship between transmission rate and ART duration was significantly non linear in the 
whole population (p=0.003), with a strong decreasing transmission rate between 0 and 12 
duration weeks, more slightly beyond 12 weeks (fig 2). Excluding premature births, only the 
linear term was significant, overall (p=0.003), as well as in the subgroup of mothers who 
delivered with viral load below 400 c/mL (p=0.02). 
 
MTCT was also associated with the time at booking visit to the obstetrical center (p=0.001), the 
lack of intrapartum prophylaxis (p=0.025), sub-Saharan African origin (p=0.009) and child 
gender (p=0.022). The higher rate of infection in female than male neonates was not due to a 
difference in perinatal mortality in males (24/2708 ; 0.7%) vs females (17/2569 ; 0.9%, p=0.4), 
or in proportion with missing HIV status. Neither maternal age, parity, mode of delivery 
(p=0.13), knowledge of HIV status before pregnancy, type of maternal ART, nor the type of 
postnatal prophylaxis were associated with MTCT.  
 
H
AL author m
anuscript    inserm
-00204104, version 1
  
Severe prematurity, HIV RNA level, global duration of ART, and child gender remained 
independently associated with MTCT in the final model of the stepwise logistic regression 
(Table 3). The adjusted odds ratio (ORa) for severe prematurity versus term delivery was 3.37 
(95%CI: 1.40-8.11) ; however, it  was not significantly different from one in mothers who 
delivered below 400 copies/mL (2.30; 95%CI: 0.29-18.48) whereas it passed to 4.60 (95%CI, 
1.78-11.84) beyond 400 copies/mL.  Elective cesarean section, not significantly associated with 
transmission in the initial model, became significantly linked to a lower risk of transmission in 
the final model. 
 
Risk factors of MTCT in term births with virological failure  
In the 364 women who term delivered with viral load > 10 000 copies/mL, the MTCT rate was: 
6.6 % (95%CI, 4.3 – 9.7%). Intrapartum prophylaxis was strongly associated with a lower risk 
of transmission: 5.3% (18/339) vs 22.7% (5/22) without intrapartum prophylaxis (p=0.009) 
(Table 2). Mothers who booked in the first trimester had a lower transmission risk (1.9%) than 
those booking in the second (9.9%) or third trimester (10.9%) (p=0.03). These two factors 
remained associated with MTCT after adjustment in both initial and final stepwise logistic 
regression models (Table 3). The adjusted OR associated with no intrapartum therapy was: 4.72 
(95%CI, 1.42-15.71; p=0.011).  
 
Risk factors of MTCT in term births with virological success  
In the 2856 mothers who term delivered with viral load below 400 copies/mL, the MTCT rate 
was 0.6% (95%CI, 0.3 – 1.0%). The rate was as low as 0.4% (5/1338; 95%CI, 0.1-0.9) in 
women who delivered with viral load below 50 c/mL. Global duration of ART was the only 
significant risk factor which remained in the initial and final models issued from stepwise 
logistic regression. The OR for each increment week was: 0.94 (95%CI, 0.90-0.99; p=0.031). 
Included in the model instead of global ART duration, time at initiation of ART or duration of 
last ART were also correlated with transmission (p=0.011 and 0.013 respectively). Including 
children with missing HIV status, as non infected, conducted to similar results. Among the more 
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homogenous subgroup of 780 women who booked at first trimester and received HAART, the 
transmission rate was: 0/392 for women already treated at the onset of pregnancy, 1.0% (2/192) 
when ART was started in the first trimester, 0.9% (1/113) in the second trimester, and 3.6% 
(3/83) in the third trimester (p=0.006). It is of interest to note that the five mothers who 
transmitted despite viral loads below 50 c/mL started therapy relatively late, between 32 and 33 
weeks. Among the infected children term born to mothers having less than 400 c/mL at 
delivery, 43% had a positive HIV1 PCR in the first 3 days, suggesting in utero transmission. 
This proportion was 21%  at 10 000 c/ml or more (fig 1).  
 
Discussion  
The objective of this study, the largest to date of HIV-1 mother-to-child transmission in the 
HAART era, was to identify risk factors for persistent cases of transmission despite the use of 
antiretroviral therapy during pregnancy. During the period 1997-2004, the rate of HIV-1 
transmission from mothers receiving any antiretroviral therapy during the pregnancy was 1.3% 
(95% CI: 1.0 -1.6). Similar rates are reported during the same period in other studies from 
industrialized countries [2, 4, 26]. Three main factors were independently related to 
transmission: high maternal plasma viral load near delivery, short duration of antenatal 
antiretroviral therapy and very premature delivery. We also found an independent association 
with gender as previously reported [27, 28, 29 ].  
Maternal viral load clearly stands out as the key determinant of mother-to-child transmission 
risk, as has been consistently reported in all studies [2, 6, 30-37]. In term births, the MTCT rate 
was 10 times higher when last maternal plasma HIV1 RNA was above rather than below 10,000 
c/mL (7.2% vs 0.8%, p<0.01). The rate was 0.5% below 400 c/mL and as low as 0.4% below 50 
c/mL.   
In French guidelines issued in the study period, zidovudine monotherapy was restricted to 
women who did not require therapy for their own health and had pre-therapeutic plasma viral 
loads below 10 000 copies/mL [38]. Thus monotherapy was indicated in women at lower risk of 
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transmitting the virus, which was likely to explain that MTCT rate did not differ according to 
the antiretroviral regimen. Be that as it may, our data confirmed that good control of maternal 
viral load is a key method to prevent MTCT, whatever the type of antiretroviral strategy used to 
obtain it.  
Maternal viral load above 10 000 c/mL at term delivery should not occur according to accepted 
guidelines  [6, 38]. This situation concerned less than 10% of mothers, but contributed to half of 
the infected children. It occurred even though 45% delivered with HAART and 27% with dual-
drug therapy, and may be due to poor adherence, multidrug resistance or treatment interruptions 
related to poor tolerance, or late access to adequate prenatal care, significantly associated with 
transmission. Intrapartum prophylaxis appeared to have a strong protective effect in case of 
virological failure. In contrast, among women with viral loads below 10 000 copies/ml, there 
was no case of transmission among the 125 women who did not receive intrapartum 
prophylaxis.   
 
MTCT rate was inversely related to duration of antenatal therapy.  Relation with very short 
zidovudine monotherapy was previously demonstrated in Thailand [8]. The non linear 
increasing risk in our survey reflected the high rate of transmission in very premature births 
with low duration:  poorer control of HIV viral load due to an unexpectedly short time between 
the start of maternal therapy and delivery may partly explain the association between 
transmission and severe prematurity. Overall, the rate was 6-fold higher when deliveries 
occurred before 33 weeks than at 37 weeks or more. Two results suggest that other factors, not 
collected in EPF during the study period, may increase perinatal exposure to HIV in severely 
preterm delivery, such as preterm premature rupture of the membranes, abruption, and chorio-
amnionitis:  the association remained significant after adjusting for duration of ART, maternal 
plasma viral load, mode of delivery and intrapartum prophylaxis ; the transmission rate was not 
increased in case of moderately premature deliveries. 
 
H
AL author m
anuscript    inserm
-00204104, version 1
  
In term births, the increasing risk of transmission with duration of therapy seemed more related 
to a very low transmission in women who were receiving ART since the first weeks of 
pregnancy.  The time needed to achieve undetectable HIV RNA by the time of delivery may 
partly account for this finding, as it is generally obtained in non pregnant adults by 10 to 16 
weeks [39].  In addition, in utero transmission may occur before therapy is initiated or effective. 
Presumed in utero transmission occurred in near one half of the children term born with 
maternal HIV1 RNA level below 400 copies/mL.  
 
Elective cesarean section tended to be associated with a lower risk of MTCT in the overall 
population. However we observed no significant difference in transmission risk according to the 
mode of delivery among women who delivered with viral load below 400 c/mL (crude OR: 
0.83; 0.29-2.39; p=0.37). A protective effect of elective cesarean section was established in our 
cohort [16] and others [17, 18], in the absence of antiretroviral prevention and in a period when 
standard care was zidovudine monotherapy.  It is unclear whether such a protective effect 
persists in women receiving ART with low viral load at delivery. Data from the PACTG [26, 
40] failed to show a difference in transmission rate according to mode of delivery in treated 
women with low viral loads. A recent study reported an association between the mode of 
delivery and mother-to-child HIV-1 transmission risk, although the association was not 
statistically significant in the subgroup of women receiving antenatal HAART [4]. In our study, 
women who received HAART and delivered with viral load below 400 c/mL had a transmission 
rate of  0.4 % (3/747) with elective caesarean and 0.5 % (3/574) with vaginal delivery  (p=0.35). 
But the power to show a 2-fold decrease was only 18%. The potential benefit of systematic 
cesarean delivery would have to be balanced with the risks, in a scenario where at least several 
hundred operations would be required to avoid one case of transmission [11, 41]. 
 
The methods available today are able to reduce mother-to-child HIV transmission to well below 
one percent. Our data confirm the major impact of achieving an undetectable maternal plasma 
viral load, with only 0.4% transmission among term-born children whose mothers had viral 
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loads below 50 c/mL at delivery. The most consistent means available to obtain such a control 
of viral replication is the use of triple combination therapy. Furthermore, our findings strongly 
suggest that antiretroviral therapy should be started relatively early, at the latest by 28 weeks, to 
obtain maximum efficacy. However, any incremental benefit of more aggressive and/or longer 
antiretroviral exposure has to be evaluated against the risks of toxicities, such as adverse events 
during pregnancy, prematurity, neonatal malformations or mitochondrial dysfunctions in 
uninfected infants  [11 , 42, 43].  The key challenge is to improve early access to specific care 
and treatment as well as adherence in pregnant women in order to achieve viral suppression 
during the last trimester of the pregnancy.  
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Legends of figures 
 
Fig 1 - MTCT rates according to HIV RNA level at delivery - The ANRS French Perinatal Cohort (1997-
2004) 
Estimations were based on 5074 available data among the 5271 included mother-child pairs who received antenatal 
ART  and did not breastfed 
HIV-1 PCR in the first 3 days was not available for 12 among 52 term born infected neonates and 7 among 15 
premature infected neonates 
 
 
 
Fig 2 - Relationship between duration of ART during pregnancy and MTCT  rate. The ANRS French 
Perinatal Cohort (1997-2004) 
The curve was estimated by a generalized additive model (GAM) with a non linear term (splines). The model was 
based on 5235 available data among the 5271 included mother-child pairs who received antenatal therapy and did 
not breastfed. 
 
Plain line:  all births (N=5 235) 
Dotted line: term births (37 weeks or more) (N = 4 554). 
Bold dotted line : term births (37 weeks or more) and maternal  HIV-1 RNA < 400 c/mL  (N = 2840). 
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Table 1 – Characteristics of HIV-1 mother-child pairs according to maternal HIV RNA level at delivery 1997-
2004† – The ANRS French Perinatal Cohort   
 
 Total  Maternal  HIV-1 RNA at delivery, copies/mL 
 
   < 400  400 - 9 999  > 10 000 
 N %  N %  N %  N % 
Year of delivery            
1997-98 1024 19.4  510 15.7  361 26.2  93 21.1 
1999-00 1293 24.5  660 20.3  438 31.8  161 36.6 
2001-02 1549 29.4  1030 31.6  348 25.3  122 37.7 
2003-04 1405 26.7  1056 32.4  231 16.8  64 14.6 
Active drug use            
Yes 144 2.7  68 2.1  50 3.6  21 4.8 
Geographical origin            
Sub-Saharan Africa 2935 55.9  1845 56.8  734 53.6  244 55.6 
Gestational age at booking, wk            
3rd trimester (> 28) 536 10.4  270 8.5  167 12.7  66 15.4 
2nd trimester (14-27) 2165 42.0  1323 41.5  583 43.2  177 41.4 
1st  trimester (<14) 2450 47.6  1592 50.0  600 44.4  185 43.2 
Gestational age at delivery, wk            
<33  122 2.3  60 1.8  30 2.2  24 5.5 
33-36  563 10.7  339 10.4  147 10.7  52 11.8 
> 37  4583 87.0  2856 87.7  1201 87.2  364 82.7 
Maternal CD4 cell count at delivery            
<200 cells/mm3 520 10.2  269 8.4  139 10.2  104 24.2 
200-349 1134 22.2  655 20.4  319 23.5  130 30.2 
> 350 3459 67.7  2284 71.2  899 66.3  196 45.6 
Gender of neonate            
Male 2684 51.3  1604 49.7  754 54.9  214 49.0 
Mode of delivery            
Elective Caesarean  2438 46.5  1409 43.5  719 52.4  230 52.6 
Emergency Caesarean  1046 20.0  633 19.5  256 18.7  117 26.8 
Vaginal delivery 1758 33.5  1201 37.0  396 28.9  90 20.6 
Initiation of antenatal ART, median wk (IQ) 22 (0-29)  21 (0-28)  24 (12-30)  23 (9-29) 
Duration of antenatal ART, median wk (IQ)  16 (9-33)  17 (10-35)  14 (8-26)  14 (8-29) 
Last antenatal ART             
HAART 2513 47.8  1842 56.7  391 28.4  196 44.6 
Dual-drug therapy 1745 33.2  1045 32.1  526 38.3  119 27.1 
Monotherapy 1003 19.1  364 11.2  458 33.3  125 28.4 
Intrapartum prophylaxis            
Yes 5006 95.6  3120 96.2  1300 95.0  407 95.6 
Postnatal child  prophylaxis             
Dual or HAART 1204 23.0  651 20.2  396 28.9  122 28.0 
Monotherapy 3990 76.3  2551 79.0  966 70.5  314 72.0 
None or late 37 0.7  28 1.0  8 0.6  0 0 
† Eligible population:  HIV-1 infected women who delivered between January 1, 1997 and December 31, 2004, and : 
(1) received at least one antenatal ART at any time during pregnancy, (2) did not breastfeed and (3) with child’s 
infection status documented. 
IQ = interquartile range 
ART=antiretroviral therapy, HAART=highly active antiretroviral therapy.   
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Table 2 – Mother-to-child transmission (MTCT) in women receiving antiretroviral therapy during the pregnancy – 
univariate analysis  - The ANRS French Perinatal Cohort (1997-2004) 
 Term births  
All births  Maternal HIV-1 RNA at 
delivery < 400 cp/mL  
 Maternal HIV-1 RNA at 
delivery > 10 000 cp/mL  
 N † n † % p #  N † n † % p #  N † n † % p # 
Total 5271 67 1.3   2856 17 0.6   364 24 6.6  
Gestational age at delivery, wk               
<33 week 122 8 6.6 <0.001           
33-36  563 7 1.2            
≥ 37  4583 52 1.1            
Maternal HIV-1 RNA at delivery                
≥ 10 000    copies/mL 440 30 6.8 <0.001           
1000-9999  938 14 1.5            
400-999      440 3 0.7            
<400           3256 19 0.6            
Active drug use               
Yes 144 2 1.4 0.71  49 0 0 1.00  20 2 10.0 0.63 
No 5125 65 1.3   2806 17 0.6   344 22 6.4  
Geographical origin               
Sub-Saharan Africa 2935 48 1.6 0.009  1642 12 0.7 0.28  199 17 8.5 0.103 
Other origin 2318 19 0.8   1208 5 0.4   164 7 4.3  
 Gestational age at booking, wk               
3rd trimester (> 28 week) 536 15 2.8 0.001  229 2 0.9 0.45  55 6 10.9 0.003 
2nd trimester (14-27) 2165 30 1.4   1169 5 0.4   142 14 9.9  
1st  trimester (<14) 2450 21 0.9   1393 10 0.7   157 3 1.9  
Maternal CD4 cell count at delivery               
<200  cells/mm3 520 16 3.1 <0.001  228 3 1.3 0.19  83 6 7.2 0.80 
200-349 1134 17 1.5   572 4 0.7   110 8 7.3  
≥350 3459 33 1.0   2015 10 0.5   164 9 5.5  
Gender of neonate               
Female 2552 42 1.7 0.022  1423 10 0.7 0.48  185 16 8.7 0.11 
Male 2684 25 0.9   1411 7 0.5   177 8 4.5  
Mode of delivery               
Elective Caesarean  2438 23 0.9 0.13  1296 7 0.5 0.90  203 10 4.9 0.37 
Emergency Caesarean  1046 18 1.7   464 3 0.7   86 8 9.3  
Vaginal delivery 1758 25 1.4   1083 7 0.7   72 5 6.9  
Initiation of antenatal ART, wk               
Non stopped from onset 1356 10 0.7 0.044  759 1 0.1 0.108  82 6 7.3 0.96 
4-20 1115 10 0.9   619 3 0.5   77 4 5.2  
21-28 1117 17 1.5   606 4 0.7   71 4 5.6  
>28 1647 29 1.8   856 9 1.1   132 9 6.8  
Median infected/non infected  27 / 22 <0.001  29 / 21 0.014  25 / 24 0.46 
Duration of antenatal ART, wk               
Median infected/non infected     9.5 / 16 <0.001  10 / 17 0.023  13 / 15 0.30 
Duration of last antenatal ART, wk              
Median infected/non infected 7 / 11 <0.001  8 / 12 0.013  8 / 10 0.47 
Last antenatal ART                
HAART 2513 30 1.2 0.77  1585 9 0.6 0.94  155 13 8.4 0.48 
Dual-drug therapy 1745 22 1.3   938 6 0.6   105 6 5.7  
Monotherapy 1003 15 1.5   328 2 0.6   104 5 4.8  
Intrapartum prophylaxis               
No 230 7 3.1 0.025  95 0 0 1.00  22 5 22.7 0.009 
Yes 5006 59 1.2   2750 17 0.6   339 18 5.3  
Postnatal child  prophylaxis                
Dual or HAART 1159 21 1.8 0.084  546 3 0.6 1.00  103 7 6.6 0.95 
Monotherapy 3975 46 1.2   2231 14 0.6   257 17 6.8  
None or late 37 0 -            
†  n indicates the number of infected children among N mother-child pairs included in the analysis 
# P-value was obtained by Fisher exact test for active drug use, gestational age, maternal HIV-1 RNA level and 
intrapartum prophylaxis, by Wilcoxon rank test for ART duration and time at initiation and by Chi-square test for 
all other variables. ART=antiretroviral therapy, HAART=highly active antiretroviral therapy.    
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Table 3 – Mother-to-child transmission (MTCT) in women receiving antiretroviral therapy during the pregnancy – Stepwise logistic regression†† - The ANRS French 
Prenatal Cohort (1997-2004) 
  Term births 
 All births 
N=4713 †  Maternal HIV-1 RNA at delivery < 400 cp/mL  
N=2659 † 
 Maternal HIV-1 RNA at delivery > 10 000 cp/mL 
N=340 †  
 Initial model † †    Final model  Initial model † †    Final model  Initial model † †    Final model 
 OR a 95% CI  OR a 95% CI p  OR a 95% CI  OR a 95% CI p  OR a 95% CI  OR a 95% CI p 
Gestational age at delivery, wk                     
<33 week 3.25 (1.32-8.03)  3.37 (1.40-8.11) 0.019               
33-36  0.84 (0.35-2.03)  0.85 (0.35-2.03)                
> 37  1 *  1                 
Maternal HIV-1 RNA at delivery                    
> 10 000    copies/mL 9.36 (4.90-17.87)  9.82 (5.24-18..37) <0.001               
1000-9999  2.46 (1.19-5.09)  2.52 (1.25-5.11)                
400-999      1.13 (0.33-3.90)  1.14 (0.33-3.90)                
<400           1 **  1                 
Active drug use        §             
Yes 1.11 (0.24-5.13)             2.11 (0.31-14.48)     
No 1 NS             1 NS     
Geographical origin                     
Sub-Saharan Africa 1.70 (0.94-3.10)  1.61 (0.92-2.83) 0.094  1.20 (0.39-3.69)      1.69 (0.53-5.40)     
Other origin 1 $$  1    1 NS      1 NS     
 Gestational age at booking, wk                     
3rd trimester (> 28 week) 1.97 (0.93-4.15)  1.95 (0.93-4.04) 0.18  0.64 (0.13-3.19)      6.54 (1.32-32.31)  8.53 (1.93-37.59) 0.010 
2nd trimester (14-27) 1.17 (0.64-2.13)  1.15 (0.64-2.09)   0.40 (0.13-1.21)      5.30 (1.36-20.72)  6.08 (1.66-22.26)  
1st  trimester (<14) 1 $      1 NS      1 *  1   
Maternal CD4 cell count at delivery                    
<200  cells/mm3 1.79 (0.88-3.62)  1.92 (0.98-3.79) 0.17  3.4 (0.8-14.1)      0.79 (0.23-2.72)     
200-349 1.15 (0.61-2.18)  1.22 (0.65-2.27)   1.7 (0.5-5.7)      1.35 (0.45-4.04)     
> 350 1 NS  1    1 NS      1 NS     
Gender of neonate                     
Female 1.98 (1.16-3.35)  1.98 (1.17-3.35) 0.011  1.39 (0.52-3.69)      2.30 (0.84-6.29)  2.21 (0.86-5.71) 0.10 
Male 1 *  1    1 NS      1 $  1   
Mode of delivery                     
Elective Caesarean  0.56 (0.29-1.06)  0.49 (0.26-0.89) 0.059  0.72 (0.24-2.16)      1.46 (0.37-5.80)     
Emergency Caesarean  0.90 (0.46-1.76)  0.81 (0.42-1.56)   0.95 (0.23-3.89)      2.59 (0.65-10.32)     
Vaginal delivery 1 $  1    1 NS      1      
Duration of antenatal ART, wk                     
For each increment week ‡ 0.96 (0.94-0.99)  0.97 (0.94-0.99) 0.010  0.93 (0.88-0.99)  0.94 (0.90-0.99) 0.031  0.98 (0.94-1.02)     
  **       *       NS     
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Last antenatal ART                      
HAART 1.22 (0.56-2.67)      1.20 (0.22-6.67)      4.01 (0.98-16.38)     
Dual-drug therapy 1.09 (0.48-2.47)      1.31 (0.23-7.44)      2.08 (0.45-9.71)     
Monotherapy 1 NS      1 NS      1 $       
Intrapartum prophylaxis                     
No 1.60 (0.66-3.89)      §       3.99 (1.09-14.65)  4.72 (1.42-15.71) 0.011 
Yes 1 NS             1 *  1   
Postnatal child  prophylaxis                      
Dual or HAART 1.33 (0.68-2.62)      1.12 (0.22-5.71)      0.96 (0.30-3.04)     
Monotherapy 1 NS      1 NS      1 NS     
†  N indicates the number of subject included in final logistic regression. ORa = adjusted odds ratio ;  95%CI = “95% confidence interval” .   
† †  The initial model included all variables listed in the table and also birth date, maternal age and parity.  
P-values in the initial models are indicated by: ** p<0.01    * 0.01<p<0.05    $$  0.05<p<0.10         $  0.10<p<0.25    NS  p>0.25 
§  The variable could not be included in the initial model since no transmission occurred in one category 
‡  Odds ratio was given for each increment week  
ART=antiretroviral therapy, HAART=highly active antiretroviral therapy.  
H
AL author m
anuscript    inserm
-00204104, version 1
  
24
 
Fig 1 - MTCT rates according to HIV RNA level at delivery - The ANRS French Perinatal 
Cohort (1997-2004) 
Estimations were based on 5074 available data among the 5271 included mother-child pairs who 
received antenatal ART  and did not breastfed 
HIV-1 PCR in the first 3 days was not available for 12 among 52 term born infected neonates and 
7 among 15 premature infected neonates 
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Fig 2 - Relationship between duration of ART during pregnancy and MTCT rate. The ANRS 
French Perinatal Cohort (1997-2004) 
The curve was estimated by a generalized additive model (GAM) with a non linear term (splines). 
The model was based on 5235 available data among the 5271 included mother-child pairs who 
received antenatal therapy and did not breastfed. 
 
Plain line:  all births (N=5 235) 
Dotted line: term births (37 weeks or more) (N = 4 554). 
Bold dotted line : term births (37 weeks or more) and maternal  HIV-1 RNA < 400 c/mL  (N = 
2840). 
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